CXCL13 (BCA-1) is produced by follicular lymphoma cells: role in the accumulation of malignant B cells

Authors

  • Hervé Husson,

    1. Department of Medicine, Harvard Medical School,
    2. Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, USA,
    Search for more papers by this author
  • Arnold S. Freedman,

    1. Department of Medicine, Harvard Medical School,
    2. Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, USA,
    Search for more papers by this author
  • Angelo A. Cardoso,

    1. Department of Medicine, Harvard Medical School,
    2. Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, USA,
    Search for more papers by this author
  • Joachim Schultze,

    1. Department of Medicine, Harvard Medical School,
    2. Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, USA,
    Search for more papers by this author
  • Olivier Munoz,

    1. Department of Medicine, Harvard Medical School,
    2. Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, USA,
    Search for more papers by this author
  • Giuliana Strola,

    1. Istituto per la Ricerca e la Cura del Cancro, Candiolo (TO),
    2. Department of Biomedical Sciences and Human Oncology, University of Torino,
    3. Division of Clinical Immunology and Hematology, Ospedale Mauriziano “Umberto I”, Torino, Italy,
    Search for more papers by this author
  • Jeffery Kutok,

    1. Department of Pathology, Harvard Medical School, and
    2. Department of Pathology, Brigham and Women's Hospital, Boston, USA
    Search for more papers by this author
  • Elizabeth G. Carideo,

    1. Department of Medicine, Harvard Medical School,
    2. Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, USA,
    Search for more papers by this author
  • Rosalie De Beaumont,

    1. Department of Medicine, Harvard Medical School,
    2. Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, USA,
    Search for more papers by this author
  • Federico Caligaris-Cappio,

    1. Istituto per la Ricerca e la Cura del Cancro, Candiolo (TO),
    2. Department of Biomedical Sciences and Human Oncology, University of Torino,
    3. Division of Clinical Immunology and Hematology, Ospedale Mauriziano “Umberto I”, Torino, Italy,
    Search for more papers by this author
  • Paolo Ghia

    1. Istituto per la Ricerca e la Cura del Cancro, Candiolo (TO),
    2. Department of Biomedical Sciences and Human Oncology, University of Torino,
    3. Division of Clinical Immunology and Hematology, Ospedale Mauriziano “Umberto I”, Torino, Italy,
    Search for more papers by this author

Arnold S. Freedman, MD, Department of Adult Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA. E-mail: arnold_freedman@dfci.harvard.edu

Abstract

Summary. Follicular lymphomas (FLs) localize in lymphoid tissues and recapitulate the structure of normal secondary follicles. The chemokine/chemokine receptor pair CXCL13/CXCR5 is required for the architectural organization of B cells within lymphoid follicles. In this study, we showed that CXCL13 was secreted by FL cells. FL cells expressed CXCR5 and migrated in response to CXCL13. Furthermore, we observed a synergistic effect between CXCL13 and CXCL12 (SDF-1), a chemokine produced by stromal cells in lymphoid tissues. The production of CXCL13 by FL cells and CXCL12 by stromal cells probably directs and participates in the accumulation of FL cells within specific anatomic sites.

Ancillary